Veradermics, Incorporated MANE
Regular-session close
Pre-market · Nov 20, 7:49 AM ET
- YTD
- +229.51%
- 1 year
- +229.51%
5D -9.75 (-7.31%)
- Market cap
- 5.25B
- EPS (ttm)
- -3.89
- Shares out
- 42.20M
- Forward P/E
- -48.19
- YTD return
- +229.51%
- 1-year return
- +229.51%
- 50-day average
- 123.76
- 200-day average
- 96.54
- Enterprise value
- 4.47B
- Volume
- 293.03K
- Avg volume
- 738.51K
- Open
- 125.98
- Previous close
- 124.86
- Day's range
- 121.91 – 128.69
- 52-week range
- 32.00 – 156.63
- Analysts
- Strong Buy
- Price target
- 187.33 (+50.6%)
- Earnings date
- Mar 29, 2027
Key statistics
- Price / book
- 6.59
- Free cash flow
- -55.22M
- Total cash
- 798.35M
- Total debt
- 371.00K
- Return on equity
- -23.12%
- Short % of float
- 12.27%
Fundamental scorecard
4 of 25 checks passed on MANE’s reported financials
4of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 172.00
- Target (mean)
- 187.33
- Target (high)
- 204.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 29, 2027
Expected Mar 29, 2027. Consensus EPS estimate -0.61597.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 29, 2027 | Mar 30, 2027 | -0.64 | — | — | — |
| Nov 10, 2026 | Sep 30, 2026 | -0.56227 | -0.50 | +0.06 | +11.07% |
| Aug 11, 2026 | Jun 30, 2026 | -0.64756 | -0.58 | +0.07 | +10.43% |
| May 12, 2026 | Mar 31, 2026 | -0.56 | -1.32 | -0.76 | -135.71% |
| Feb 25, 2026 | Dec 31, 2025 | -1.81 | -1.63 | +0.19 | +10.31% |
| Dec 3, 2025 | Sep 30, 2025 | — | -1.63 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Citigroup | main | Buy | Buy |
| Nov 9, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 22, 2026 | B. Riley Securities | main | Buy | Buy |
| Oct 19, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 19, 2026 | Needham | main | Buy | Buy |
| Jul 16, 2026 | Citigroup | main | Buy | Buy |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- veradermics.com
News
Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? Citigroup Maintains Buy on Veradermics, Raises Price Target to $175
Leerink Partners Maintains Outperform on Veradermics, Raises Price Target to $150
Veradermics Eyes Historic FDA First After Strong Hair Loss Pill Trial Results Veradermics Announces Topline Results From Registration-Directed Phase 2/3 Trial Of VDPHL01, Demonstrating Efficacy In Male Pattern Hair Loss
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204
Your note
Sign in to keep a note on MANE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHILDS JOHN W | Director | Sale | Aug 11, 2026 | 0 |
| CORIC VLADIMIR | Director | Purchase | Feb 4, 2026 | 0 |
| DURSO TIMOTHY AUGUST | Chief Technology Officer | Conversion of Exercise of derivative security | Aug 16, 2026 | 78,142 |
| ENRIGHT PATRICK G. | Director | Sale | Nov 10, 2026 | 0 |
| GRANT-KELS JANE M. M.D. | Director | Conversion of Exercise of derivative security | Feb 4, 2026 | 2,455 |
| LONGITUDE CAPITAL PARTNERS V, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 4, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 8.81% | 3,718,970 | 462.57M | Sep 29, 2026 |
| FMR, LLC | 7.26% | 3,062,338 | 380.89M | Sep 29, 2026 |
| JPMORGAN CHASE & CO | 5.62% | 2,372,707 | 295.12M | Sep 29, 2026 |
| SR One Capital Management, LP | 4.93% | 2,080,119 | 258.73M | Sep 29, 2026 |
| Citadel Advisors Llc | 4.85% | 2,048,475 | 254.79M | Sep 29, 2026 |
| Blackrock Inc. | 4.57% | 1,929,832 | 240.03M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.95% | 824,223 | 102.52M | Sep 29, 2026 |
| abrdn Healthcare Investors | 1.49% | 627,841 | 78.09M | Jun 29, 2026 |
| abrdn Healthcare Opportunities Fund | 1.49% | 626,977 | 77.98M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.47% | 618,416 | 76.92M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.35% | 570,376 | 70.94M | Sep 29, 2026 |
| abrdn World Healthcare Fund | 0.81% | 341,883 | 42.52M | Jun 29, 2026 |
